Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy
Open Access
- 1 May 1996
- journal article
- Published by Elsevier in The Lancet
- Vol. 347 (9013) , 1453-1458
- https://doi.org/10.1016/s0140-6736(96)91687-6
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- A potent far-upstream enhancer in the mouse pro alpha 2(I) collagen gene regulates expression of reporter genes in transgenic mice.The Journal of cell biology, 1996
- THE MANAGEMENT OF SYSTEMIC SCLEROSISRheumatology, 1995
- The aetiopathogenesis of systemic sclerosisJournal of Internal Medicine, 1993
- Minimal DNA sequences that control the cell lineage-specific expression of the pro alpha 2(I) collagen promoter in transgenic mice.The Journal of cell biology, 1992
- Radical Microarteriolysis in the Treatment of Vasospastic Disorders of the Hand, Especially SclerodermaJournal of Hand Surgery (European Volume), 1992
- Interleukin‐1, Interleukin‐2, Interleukin‐4, Interleukin‐6, Tumor Necrosis Factor α, and Interferon‐γ Levels in Sera from Patients With SclerodermaArthritis & Rheumatism, 1992
- Differential utilization of regulatory domains within the alpha 1(I) collagen promoter in osseous and fibroblastic cells.The Journal of cell biology, 1992
- Elevated proα2(I) collagen mRNA levels in cultured scleroderma fibroblasts result from an increased transcription rate of the corresponding geneFEBS Letters, 1987
- Activation of type I collagen genes in cultured scleroderma fibroblastsJournal of Cellular Biochemistry, 1985
- Chronic graft-versus-host disease (GVHD) as a model for sclerodermaCellular Immunology, 1983